lidocaine has been researched along with Alzheimer Disease in 9 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications." | 4.85 | Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009) |
| "In the brains of patients with Alzheimer's disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased." | 1.46 | N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents. ( Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A, 2017) |
| " Moreover, hERG and BBB-PAMPA assays presented safe cardiotoxicity and high CNS bioavailability profiles for 5x." | 1.46 | Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction. ( Elkamhawy, A; Hassan, AHE; Lee, J; Moon, B; Pae, AN; Park, BG; Park, HM; Park, JE; Ra, H; Roh, EJ, 2017) |
| "Alzheimer's disease is a fatal neurodegenerative disorder with a complex etiology." | 1.42 | Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents. ( Bajda, M; Brus, B; Gobec, S; Guzior, N; Malawska, B; Rakoczy, J, 2015) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | 1.42 | Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guzior, N | 1 |
| Bajda, M | 2 |
| Rakoczy, J | 1 |
| Brus, B | 3 |
| Gobec, S | 4 |
| Malawska, B | 3 |
| Więckowska, A | 2 |
| Więckowski, K | 2 |
| Sałat, K | 1 |
| Czerwińska, P | 1 |
| Filipek, B | 1 |
| Kołaczkowski, M | 1 |
| Bucki, A | 1 |
| Godyń, J | 1 |
| Marcinkowska, M | 1 |
| Zaręba, P | 1 |
| Siwek, A | 1 |
| Kazek, G | 1 |
| Głuch-Lutwin, M | 1 |
| Mierzejewski, P | 1 |
| Bienkowski, P | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Knez, D | 2 |
| Wichur, T | 1 |
| Košak, U | 1 |
| Coquelle, N | 1 |
| Pišlar, A | 1 |
| Nachon, F | 1 |
| Brazzolotto, X | 1 |
| Kos, J | 1 |
| Colletier, JP | 1 |
| Elkamhawy, A | 1 |
| Park, JE | 1 |
| Hassan, AHE | 1 |
| Ra, H | 1 |
| Pae, AN | 1 |
| Lee, J | 1 |
| Park, BG | 1 |
| Moon, B | 1 |
| Park, HM | 1 |
| Roh, EJ | 1 |
| Abernethy, AP | 1 |
| Farrell, TW | 1 |
| Takaya, T | 1 |
| Okamoto, M | 1 |
| Yodoi, K | 1 |
| Hata, K | 1 |
| Kijima, Y | 1 |
| Nakajima, H | 1 |
| Nishikawa, Y | 1 |
| Kita, T | 1 |
| Ito, M | 1 |
| Seo, T | 1 |
| Kawashima, S | 1 |
| Benedetti, F | 1 |
| Arduino, C | 1 |
| Costa, S | 1 |
| Vighetti, S | 1 |
| Tarenzi, L | 1 |
| Rainero, I | 1 |
| Asteggiano, G | 1 |
1 review available for lidocaine and Alzheimer Disease
| Article | Year |
|---|---|
Pain and palliative care pharmacotherapy literature summaries and analyses.
Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi | 2009 |
1 trial available for lidocaine and Alzheimer Disease
| Article | Year |
|---|---|
Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analgesics; Attitude; Brain Mapping; Case-Control Studie | 2006 |
7 other studies available for lidocaine and Alzheimer Disease
| Article | Year |
|---|---|
Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Delivery Systems; Drug | 2015 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrie | 2015 |
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cataly | 2016 |
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cell Death; Cell Line; Cholinestera | 2017 |
Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cyclosporine; Dru | 2017 |
Torsades de Pointes with QT prolongation related to donepezil use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Colitis; Donepezil; Electrocardiogr | 2009 |
When expectation fails.
Topics: Alzheimer Disease; Anesthetics, Local; Humans; Lidocaine; Placebo Effect; Prefrontal Cortex | 2006 |